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The duodenal stump after Billroth II (B-II) distal gastrectomy is a rare site for cancer recurrence unless a tumor-free margin has not been achieved. Moreover, to our knowledge, there are no previously published studies regarding the occurrence of recurrent or metachronous cancer at the duodenal stump. Here, we describe duodenal stump cancer that occurred after a B-II distal gastrectomy for advanced gastric cancer (AGC), particularly focusing on the diffi culties associated with distinguishing recurrent gastric cancer from metachronous duodenal cancer.
Case report
A 68-year-old man who had undergone distal gastrectomy with B-II type gastrojejunostomy for AGC in June 2005, presented with abrupt onset of dizziness and tarry stool in June 2008. The previously removed tumor was 8.5 × 7.5 cm in size, and located in the posterior wall of the mid-body portion of the stomach, and there was no duodenal lesion on the gastrofi berscopic (GFS) examination that had been performed before the gastrectomy. Pathologic examination revealed that the gastric lesion was a poorly differentiated adenocarcinoma infi ltrating the subserosa, accompanied by multiple lymph node metastases (48 of 77 retrieved nodes were metastatic); the duodenum was resected, using a linear stapler, about 2 cm below the pyloric ring. The proximal and distal resected margins were 1.5 cm and 8.0 cm, respectively. Subsequently, six cycles of adjuvant chemotherapy, including 5-fl uorouracil (FU), epirubicin, and cisplatinum, were performed without any problems. The patient was followed up every 6 months by tumor marker analysis, ultrasonography, and computed tomography (CT) and his last checkup had been in January 2008. During 
Introduction
Recently, the identifi cation of early gastric cancer (EGC) in Korea has been rapidly increasing by virtue of nationwide gastrofi berscopic examinations. However, many patients still suffer from advanced cancer and postoperative cancer recurrences. Even patients with the follow-up period, there had been no evidence of recurrence.
On admission, his laboratory fi ndings were unremarkable, except for low hemoglobin (7.2 g/ml) and hematocrit (23.4%), which was managed with the transfusion of 5 units of packed RBC. GFS examination demonstrated a polypoid mass at the duodenal stump that bled easily when touched (Fig. 1A) . Abdominal CT scan also revealed a mass at the duodenal stump (Fig. 1B) that had not been detected on the previous CT performed 6 months earlier. A biopsy of the polypoid mass revealed moderately differentiated adenocarcinoma. After confi rmation of the absence of any other metastatic lesions by positron emission tomography (PET)-CT (Fig. 1C) , we decided to remove the tumor because the patient needed a transfusion due to bleeding and it was thought that a palliative operation might be helpful to correct his anemia. When exploration of the abdominal cavity was carried out in June 2008, there were no fi ndings suggesting that the tumor was inoperable, with no evidence of peritoneal seeding or of any sites of recurrence except for the duodenal lesion. Therefore, we performed pancreaticoduodenectomy with curative intent; the specimen obtained was 3.0 × 2.5 × 3.5 cm in size, and the tumor had invaded the peripancreatic soft tissues (Fig. 1D ). There were three lymph node metastases out of seven retrieved lymph nodes, with lymphatic and perineural invasion. Pathologic analysis was used to compare the previous gastric lesion with the duodenal mass obtained in the present operation. HematoxylinEosin ( Fig. 2A, B) and immunohistochemical (Fig.  3A-D) staining strongly indicated that the obtained specimen represented a metachronous duodenal cancer rather than a recurrent one. The patient is free of recurrence now, 10 months after the second operation.
Discussion
Gastric cancer patients who have undergone gastrectomy have a risk of recurrence, especially those who have advanced disease. It is well known that peritoneal recurrence is most common, followed by hematogenous and lymph node recurrence [4] . Because of these risks, generally, modalities such as CT, ultrasound, and tumor marker (carcinoembryonic antigen) analysis have been used for follow up after gastrectomy. Recently, PET-CT, which has the advantage of being able to detect lesions that are not distinguished by CT, was introduced. PET-CT may be useful for gastric cancer patients in whom there is a clinical suspicion of recurrence [5] . However, PET-CT has limitations for the detection of recurrence if the histopathologic types of gastric cancer are mucinous and signet ring cell carcinoma, as well as poorly differentiated adenocarcinoma [6] . Therefore, there are still no sure tools for the detection of recurrence despite the availability of these diagnostic methods. In the present patient, sudden elevation of carbohydrate antigen 19-9 had been observed 30 months postoperatively. The patient had undergone abdominal CT with a suspicion of recurrence, but the CT did not reveal a lesion. Because the histopathologic type of gastric cancer that had been resected previously was poorly differentiated adenocarcinoma, we elected not to perform PET-CT, and we planned attentive followup measures. Six months after, a suspicious lesion was detected by both abdominal CT and PET-CT.
Our clinical opinion was that the duodenal stump mass in the present patient was a recurrent cancer resulting from invasion of the lymph nodes around the duodenal stump, which had been incompletely removed previously. However, pathologic examination with hematoxylin-eosin staining confl icted with our concept. So we carried out immunohistochemical staining including staining with MUC5AC, MUC6, and MUC2 to identify the origin of this tumor and compare it with the previous lesion. Gastrointestinal carcinomas are pathologically classifi ed into four categories based on mucin type: mixed, gastric, intestinal, and unclassifi ed, and prognosis of gastrointestinal carcinomas (or that) can be based on these subtypes [7] . In our immunohistochemical study, the tumor cells from both organs exhibited the gastric type. However, the staining patterns of the two tumors were different. The gastric cancer was partially stained by MUC6 alone. In contrast, the duodenal lesion displayed diffusely positive MUC5AC and MUC6 staining. These results were also suggestive of a metachronous tumor from the pathologic aspect.
Although the possibility of local recurrence at the duodenal stump was challenged by our pathologic fi ndings, a review of the literature revealed that most duodenal cancers arise in the second portion of the duodenum and some occur in the third or fourth portion, but none occur in the fi rst portion [8] [9] [10] . In addition to recurrence, metachronous cancer may develop in gastric cancer patients. Recently, some studies have reported that the risk of metachronous cancer associated with gastric cancer is elevated with increasing age, and this would negatively infl uence the prognosis of gastric cancer patients [1] [2] [3] . In published reports, the incidence of metachronous cancer occurring after gastric cancer is 1.4%-4.2%, and it tends to occur more frequently in patients with EGC [1] [2] [3] . The colorectum is the most common site, followed by the lung and liver [1, 2] . However, a signifi cant correlation between metachronous duodenal cancer and gastric cancer has not yet been established, even though synchronous duodenal cancer associated with gastric cancer has been reported [11] . On consideration of these clinical features of duodenal cancer and the relationship with gastric cancer, we have not yet clarifi ed the origin of the duodenal stump lesion in our patient, although the pathologic fi ndings strongly suggested that the tumor was metachronous.
Recurrence is the most feared factor in patients with gastric cancer and, unfortunately, most recurrences are at multiple sites at the time of diagnosis [12] . The standard treatment for recurrence has not been well established, but, on the other hand, a few studies have demonstrated that, in cases of localized recurrence, complete resection, when achievable, may be benefi cial to the patient's survival [13, 14] . Because the lesion in our patient was regarded as a localized recurrence, we performed the operation and patient has not shown any signs of recurrence as yet.
In summary, the unusual location of the duodenal stump, including the surrounding lymph nodes, makes it diffi cult to differentiate metachronous duodenal cancer from recurrence in this region. However, regardless of its origin, the rare case presented herein was successfully managed by pancreaticoduodenectomy. Routine follow up with attention may be helpful for early detection and treatment in such types of cases.
